These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. What is a case-control study? Comment on 'Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study'. Myles PS Anaesth Intensive Care; 2024 Jan; 52(1):73. PubMed ID: 38000004 [No Abstract] [Full Text] [Related]
5. Response to "What is a case-control study? Comment on 'Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study'". Wood AJ; Rauniyar R; Jacques A; Palmer RN; Wibrow B; Anstey MH Anaesth Intensive Care; 2024 Jan; 52(1):74. PubMed ID: 37999999 [No Abstract] [Full Text] [Related]
6. Historical Aspects of Ascites and the Hepatorenal Syndrome. Wong F; Blendis L Clin Liver Dis (Hoboken); 2021 Oct; 18(Suppl 1):14-27. PubMed ID: 34745581 [TBL] [Abstract][Full Text] [Related]
7. Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis. Shrestha DB; Budhathoki P; Sedhai YR; Baniya RK; Karki P; Jha P; Mainali G; Acharya R; Sodhi A; Kadaria D Cureus; 2022 Jul; 14(7):e27483. PubMed ID: 36060403 [TBL] [Abstract][Full Text] [Related]
8. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Benmassaoud A; Freeman SC; Roccarina D; Plaz Torres MC; Sutton AJ; Cooper NJ; Iogna Prat L; Cowlin M; Milne EJ; Hawkins N; Davidson BR; Pavlov CS; Thorburn D; Tsochatzis E; Gurusamy KS Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013123. PubMed ID: 31978257 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Sourianarayanane A; Barnes DS; McCullough AJ Gastroenterol Hepatol (N Y); 2011 Feb; 7(2):132-4. PubMed ID: 21475423 [No Abstract] [Full Text] [Related]
10. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001 [TBL] [Abstract][Full Text] [Related]
11. [Hepatorenal syndrome: diagnosis, treatment and prevention]. Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840 [TBL] [Abstract][Full Text] [Related]
12. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. Kalambokis GN; Tsianos EV Hepatology; 2008 Aug; 48(2):686. PubMed ID: 18666233 [No Abstract] [Full Text] [Related]
13. [Vasoconstrictors in the treatment of hepatorenal syndrome]. Ortega R; Calahorra B; Ginès P Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919 [No Abstract] [Full Text] [Related]
14. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1. Kalambokis GN; Baltayiannis G; Christodoulou D; Christou L Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1428-1429. PubMed ID: 29111999 [No Abstract] [Full Text] [Related]
15. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. Testro AG; Angus PW J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956 [No Abstract] [Full Text] [Related]